BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, April 22, 2026
Home » Topics » Deals and M&A

Deals and M&A
Deals and M&A RSS Feed RSS

Nanox.Arc

Nanox reimagines radiology with two acquisitions

Aug. 10, 2021
By Annette Boyle
Continuing its push to streamline the imaging industry from equipment to vertical integration, Nano-x Imaging Ltd. (Nanox) agreed to acquire Zebra Medical Vision Ltd. and signed a letter of intent to buy Usarad Holding Inc. and its related company Medical Diagnostics Web. The timing of the transactions, designed to create an end-to-end radiology solution, was not announced.
Read More
Single strand RNA

Low-profile mRNA developer Greenlight going public in $1.5B SPAC merger

Aug. 10, 2021
By Lee Landenberger
MRNA’s the thing and special purpose acquisition company (SPAC) Environmental Impact Acquisition Corp. is following as it will merge with privately held mRNA-developer Greenlight Biosciences Inc.
Read More
AI silhouette

Nihon Kohden buying predictive analytics company AMP3D

Aug. 9, 2021
By Meg Bryant
Nihon Kohden Corp. has acquired Advanced Medical Predictive Devices, Diagnostics and Displays Inc. (AMP3D) for an undisclosed sum. The company provides data analytics and artificial intelligence solutions for proactive clinical care. Charlottesville, Va.-based AMP3D owns a large library of clinical predictive algorithms, as well as the Continuous Monitoring of Event Trajectories predictive analytics platform. The latter, a software-as-a-service platform, leverages patients’ continuous monitoring data, vita signs, medical records and laboratory tests to display patients’ risk trajectories, both in current and continuous time.
Read More
Neurology illustration

Mission’s DUB deal with Abbvie scores $20M milestone

Aug. 9, 2021
By Nuala Moran
LONDON – Mission Therapeutics Ltd. has honed down a collection of 100-odd deubiquitylating (DUB) enzymes, to identify two that degrade misfolded proteins in Parkinson’s and Alzheimer’s diseases, triggering a $20 million milestone from partner Abbvie Inc.
Read More

Philip Morris buys Otitopic and its cardiology inhaler as bidding war for Vectura heats up

Aug. 9, 2021
By Richard Staines
Tobacco firm Philip Morris International Inc. has announced another acquisition as it adopts a “beyond nicotine” strategy, snapping up Otitopic Inc., of Los Angeles, for an undisclosed sum.
Read More
Disitamab vedotin

In a $2.6B deal, Seagen and Remegen target HER2 with an ADC

Aug. 9, 2021
By Lee Landenberger
Seagen Inc. and Remegen Co. Ltd. will collaborate to exclusively develop and commercialize disitamab vedotin, a humanized antibody-drug conjugate (ADC) targeting HER2, giving Remegen the chance to earn up to $2.4 billion in total milestone payments.
Read More
Handshake dollar sign

Eqrx Nasdaq listing in the PIPEline with $1.8B SPAC deal

Aug. 6, 2021
By Michael Fitzhugh
Eqrx Inc., a startup co-founded by serial biotech entrepreneur and investor Alexis Borisy to deliver new medicines for cancer and other conditions at "radically lower prices," is poised to raise up to $1.8 billion via a merger with the special purpose acquisition company (SPAC) CM Life Sciences III Inc. The transaction, which would bring Eqrx to Nasdaq, includes a fully committed and upsized PIPE of $1.2 billion led by Softbank Group's SB Management Ltd. as well as SPAC sponsors Casdin Capital LLC and Corvex Management LP, plus $550 million of cash and trust held by the SPAC itself.
Read More
Acquisition target

Medtronic’s $1.1B buy of Intersect would solidify its footprint in ENT space

Aug. 6, 2021
By Mark McCarty
Medtronic plc reported it will acquire Intersect ENT, a deal that represents a major expansion of Medtronic’s footprint in the ear/nose/throat (ENT) space. Intersect’s products for chronic rhinosinusitis will give Medtronic access to a medical market said to be among the top 10 most expensive conditions for employers, with a potential patient population of 35 million in the U.S. alone.
Read More

Questions over Morphosys’ $1.7B BET deal as Sierra snaps up AZ’s rival for $8M

Aug. 6, 2021
By Richard Staines
Sierra Oncology Inc. has swooped in on an early stage BET inhibitor from Astrazeneca plc, paying just $8 million up front for the myelofibrosis drug – a price that raises questions about the $1.7 billion Morphosys AG stumped up to buy Constellation Pharmaceuticals and its class rival.
Read More
Handshake, businessmen holding dollar sign, lightbulb

IPO no-go, Bayer swayer in $2B Vividion deal

Aug. 5, 2021
By Randy Osborne
A little over a month after Versant Ventures-back Vividion Therapeutics Inc. filed to raise $100 million in an IPO, Bayer AG is paying $1.5 billion up front, with the promise of $500 million more in milestone payments, to take over the firm and its small-molecule precision oncology and immunology platform.
Read More
Previous 1 2 … 229 230 231 232 233 234 235 236 237 … 323 324 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 22, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing